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with the initial dosing regimen was measured using the Medica-
tion Possession Ratio (MPR). To identify determinants of non-
compliance, non-compliant patients (MPR < 50%) were
compared to compliant patients (MPR °Y´ 80%). The effect of
dosing regimen, patient age, prescriber, co-medication and frac-
tures on non-compliance was investigated. For independent
factors increasing non-compliance the Population Attributable
Risk percentage (PAR%) was determined. RESULTS: The study
cohort included 4699 (53%) compliant and 3089 (35%) non-
compliant users of daily or weekly bisphosphonates. A total of
1034 (12%) patients had a MPR °Y´ 50% and <80% over the
ﬁrst year. Use of daily bisphosphonates, number of different co-
medications used, and use of gastrointestinal medication during
the ﬁrst year were associated with an increased risk of non-
compliance (OR 3.1, 95% CI 2.7–3.5; OR 1.8, 95% CI 1.3–2.3
for >10 different co-medications; and OR 1.2; 95% CI 1.1–1.4,
respectively). Corresponding PAR% were 42%, 14% and 6%,
respectively. In contrast, higher age, ﬁrst prescription from a 
specialist, use of NSAIDs and hospitalization for osteoporosis 
or osteoporotic fracture in the year preceding bisphosphonate
therapy independently decreased the risk of non-compliance.
CONCLUSIONS: These results indicate that daily, rather than a
weekly, dosing regimen is the most important independent 
determinant of non-compliance with bisphosphonates. However,
compliance for both regimens can be considered to be subopti-
mal and leaves room for improvement.
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OBJECTIVES: Thrombocytopenia is a serious complication that
may occur in patients receiving venous thromboembolism pro-
phylaxis for a variety of reasons, including drug-induced throm-
bocytopenia. This analysis was conducted to assess if differences
exist in the coded rates of thrombocytopenia in patients receiv-
ing fondaparinux, dalteparin, enoxaparin, or unfractionated
heparin (UFH). METHODS: This was a retrospective analysis of
inpatient data from >500 hospitals in the United States. Patients
hospitalized for hip or knee replacement or hip fracture surgery
between 1/2003 and 3/2005 were eligible for study inclusion.
Patients receiving fondaparinux, dalteparin, enoxaparin or UFH
<2 days after surgery were included. A control group of ortho-
pedic surgery patients that did not receive any of the anticoagu-
lants of interest was also identiﬁed. Patients <18yrs of age or
those receiving >1 anticoagulant of interest during their hospi-
talization were excluded. The occurrence of thrombocytopenia
was determined by the presence an ICD-9 code for thrombocy-
topenia unspeciﬁed (287.5) and/or secondary thrombocytopenia
due to circulating anticoagulants (287.4 with E934.2). Logistic
regression models were used to assess differences in thrombocy-
topenia rates; controlling for age, gender, severity of illness
(Charlson), length of stay, number of hospitalizations prior to
index visit, type of orthopedic surgery, and cancer diagnosis.
RESULTS: A total of 250,600 patients were included in the
analysis: fondaparinux = 11,633; dalteparin = 14,713; enoxa-
parin = 92,776; UFH = 18,904; control = 112,574. The unad-
justed rates of thrombocytopenia in each cohort were:
fondaparinux = 0.8%, dalteparin = 1.2%, enoxaparin = 1.4%,
UFH = 1.3%, control = 0.9%. After controlling for baseline
covariates, patients on fondaparinux were least likely to experi-
ence thrombocytopenia. The odds of thrombocytopenia for each
anticoagulant when compared to control were: fondaparinux
OR = 0.98, p = 0.83; dalteparin OR = 1.2, p = 0.02; enoxaparin
OR = 1.3, p < 0.0001; UFH OR = 1.2, p = 0.03. CONCLU-
SIONS: Although the relative rates of drug-induced thrombocy-
topenia cannot be deﬁned with certainty (coding limitations), the
risk of thrombocytopenia in fondaparinux-treated patients was
similar to control, while patients receiving heparins experienced
an increased risk.
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OBJECTIVE: To estimate the economic and health impact of
managing bradycardia by implanting a dual chamber pacemaker
equipped with a new algorithm (Adapta) to avoid unnecessary
right ventricular pacing compared to a standard dual chamber
pacemaker (DDDR) in Sweden. The algorithm allows the pace-
maker to provide atrial pacing, and switch to dual-chamber
pacing whenever needed. This may lower the risk of developing
heart failure or atrial ﬁbrillation. METHODS: A life-time dis-
crete event simulation was developed to follow a patient’s course
after implantation with a pacemaker. Pairs of identical patients
are created; one receives Adapta, the other DDDR. Each patient
may develop post-operative complications, heart failure, atrial
ﬁbrillation (which may become chronic and require anticoagu-
lants) or have a stroke. Risks for these events depend on cumu-
lative time exposed to ventricular pacing and patient’s
characteristics based on published data from the MOST trial.
Life expectancy is assumed to be identical for both cohorts of
patients. Distributions of ventricular pacing are based on data
collected during trials of these devices. Direct medical costs
drawn from published NORD-DRG payments and physician,
laboratory and medication tariffs are reported in 2005 SEK and
discounted at 3%. RESULTS: Average life expectancy post-
implantation was found to be 11.8 years for both groups. Dis-
counted costs over life-time were about SEK200,000 (€21,220)
per patient. Despite the higher initial cost of Adapta, mean addi-
tional cost was only SEK13,430 (€1425) per patient. Adapta 
is predicted to increase QALY by a mean 0.23 years, yielding 
an incremental cost-effectiveness ratio of SEK45,961/QALY
(€4878/QALY). Sensitivity analyses showed results were consis-
tent over a wide range of values. CONCLUSION: Based on these
discrete event simulations estimates, Adapta is predicted to
provide additional health beneﬁts for an attractive value for
patients with sinoatrial-node disease or intermittent atrioven-
tricular block.
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OBJECTIVE: Lymphatic Filariasis (LF), an eradicable infectious
disease endemic in developing countries, is associated with sig-
niﬁcant morbidity. LF is the second leading cause of permanent
and long-term disability worldwide. Total global prevalence of
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the disease is 120 million with over a third of those affected
having severe chronic disease. We attempted to estimate the
actual disease burden in three countries, with varying levels of
disease prevalence, so that the impact of LF in these countries
can be better understood. METHODS: We constructed an eco-
nomic model of work lost due to LF in three countries where it
is prevalent (India, Ghana, and Thailand). Data sources included
published studies on productivity among individuals who expe-
rience LFs debilitating manifestations in the form of acute ade-
nolymphangitis [(ADL) or chills and fevers often with swelling
of the affected limb and associated lymph node inﬂammation]
and chronic lymphatic obstruction (which can lead to hydrocele
and elephantiasis). Wages used for our calculations were the
minimum agricultural wages obtained from the International
Labor Organization and converted to 2005 US$. The time
horizon used was one year. RESULTS: The estimated period
prevalence of chronic lymphatic obstruction secondary to LF
among people between the ages of 15–65 years in India, Ghana
and Thailand was estimated at approximately 77,779,036;
1,917,923; and 549,733 respectively. Wages lost attributable to
lymphatic obstruction were estimated to be $4.5 billion; $261
million; and $174 billion respectively. Additional annual wages
lost attributable to ADL are approximately $22 million; $1
million; and $855,150 in these countries respectively. CON-
CLUSION: The model demonstrated that LF results in signiﬁ-
cant and costly work impairments. As one of only six global
diseases that meet the criteria for being eradicable, our research
on the economic impact of LF suggests that policymakers should
make investments in initiatives aimed at preventing and treating
this disease.
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OBJECTIVE: To determine the prevalence of organ-threatening
and mental health co-morbidities and examine their effects on
total medical costs in systemic lupus erythematosus (SLE)
patients. METHODS: A total of 2395 California Medicaid
patients with a diagnosis of SLE were included in this retro-
spective analysis. Diagnosis of mental co-morbidities (depres-
sion, anxiety, and fatigue) was based on ICD-9 codes from the
claims record as was the presence of organ involvement (heart,
lung, kidney, liver, and serious blood involvement). The analyses
were conducted from an insurer’s perspective; payments were
used as a proxy measure for costs. Total medical costs included
inpatient costs, ambulatory and outpatient costs, prescription
costs, and nursing facility/intermediate care facility costs.
Descriptive analysis was performed to determine the prevalence
of these co-morbidities. The effect of mental and organ-threat-
ening co-morbidities on total medical costs of SLE patients was
modeled using a mixed regression estimation controlling for age,
gender, ethnicity, and eligibility in both Medicaid and Medicare.
RESULTS: The incidence rates for depression, anxiety and
fatigue were 14.7%, 8.2%, and 15.8%, respectively. About 37%
of the patients have at least one affected organ. Pulmonary man-
ifestation was the most common organ involvement, occurring
in 20.4% of the SLE patients. About 11% of the patients 
had kidney involvement while 18% had heart involvement.
Higher incidence rates of fatigue was observed in patients with
organ-threatening SLE (21.6% vs. 12.5%, p < 0.01). Organ-
involvement results in an average increase of $1144/per month
in total medical costs (p < 0.01). Among the three mental co-
morbidities, fatigue is signiﬁcantly associated with increased
total costs of $536 (p < 0.0001). The ethnicity inﬂuence on total
medical costs dissipates with the inclusion of organ-threatening
co-morbidities and fatigue. CONCLUSIONS: Both mental
health and organ involvement co-morbidities are signiﬁcant pre-
dictors of medical costs of treating SLE.
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OBJECTIVES: Examine frequency and costs of disability among
employed individuals with COPD. METHODS: Retrospective
analysis of disability and medical claims data for employees of
nine national self-insured companies. Active employees 
40–63 years old with diagnosis of COPD (ICD-9-CM: 491.xx,
492.x,496) between January 1, 2001–December 31, 2003 were
identiﬁed. Index date was later of: 1) ﬁrst COPD diagnosis, or
2) ﬁrst date of eligibility for short-term disability (STD), long-
term disability (LTD), and health beneﬁts. Employees with cystic
ﬁbrosis, lung cancer, tuberculosis, or pregnancy, and those con-
tinuously eligible for <90 days following index date, were
excluded. Using propensity score matching, controls were
matched 2 :1 to COPD subjects on age, gender, geographic
region, employer, length of employment, and salary range. Sub-
jects were followed until the earliest of non-active employee
status, disenrollment from any beneﬁt, 365 days of follow-up,
or March 31, 2004. Likelihood of disability was compared
between COPD subjects and controls using logistic regression,
adjusting for length of follow-up and speciﬁc comorbidities. Indi-
rect costs of disability, measured as disability days multiplied by
subjects’ daily wage, were compared among subjects with a dis-
ability claim using GLM with a gamma distribution and log link,
adjusting by the aforementioned covariates. RESULTS: Mean
length of follow-up for COPD subjects (n = 1349) and controls
(n = 2696) was 220 and 233 days. Mean age was 52 years, and
cohorts approximately 50% male. All comorbidities were more
common in the COPD cohort. A greater proportion of COPD
subjects used STD (21.8% vs. 7.0%), LTD (2.4% vs. 0.4%), 
or any disability beneﬁt (22.8% vs. 7.3%). Odds ratios for like-
lihood of disability for COPD subjects were: STD, 2.11 (95%
CI: 1.64–2.71); LTD, 4.21 (1.93–9.16); any disability, 2.15
(1.68–2.75). CONCLUSIONS: Among those with disability
(307 COPD patients, 197 controls), indirect costs were higher
among COPD subjects ($8559) than controls ($5443); this
approached signiﬁcance (p = 0.07).
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OBJECTIVES: The Australian national reimbursement system
has tended to evolve independently from other health care
funding environments. Over the past few years, a range of policy
initiatives has been introduced. Many of these have been aimed
directly at restricting the growth in drug expenditures.
METHODS: This study examines the range of initiatives and
estimates the savings that each has produced. The authors have
built a large relational database that captures all pricing, utili-
